Results 61 to 70 of about 8,397 (218)
Frontiers in Immunology, 2014 Leishmaniasis has several clinical forms: self-healing or chronic cutaneous leishmaniasis or post-kala-azar dermal leishmaniasis; mucosal leishmaniasis; and visceral leishmaniasis, which is fatal if left untreated.
Bruno Mendes Roatt +14 more
doaj +1 more source
Further Evidence of an Association between the Presence of Leishmania RNA Virus 1 and the Mucosal Manifestations in Tegumentary Leishmaniasis Patients. [PDF]
PLoS Neglected Tropical Diseases, 2015 Tegumentary Leishmaniasis (TL) is endemic in Latin America, and Brazil contributes approximately 20 thousand cases per year. The pathogenesis of TL, however, is still not fully understood. Clinical manifestations vary from cutaneous leishmaniasis (CL) to
Lilian Motta Cantanhêde +8 more
doaj +1 more source
Applied Organometallic Chemistry, Volume 40, Issue 7, July 2026.1,2‐Disubstituted ferrocene analogues bearing hydantoin or rhodanine synthons were synthesised and assessed for antitrypanosomatid activity. An antileishmanial early lead, analogue 23, acting through ROS generation and hence oxidative stress, was uncovered.
Maryna Saayman +7 more
wiley +1 more source
The role of leishmania proteophosphoglycans in sand fly transmission and infection of the Mammalian host. [PDF]
, 2012 Leishmania are transmitted by the bite of their sand fly vector and this has a significant influence on the virulence of the resulting infection. From our studies into the interaction between parasite, vector, and host we have uncovered an important ...
Rogers, Matthew E +2 more
core +1 more source
The Effect of Designed Home Visit Program on Promoting Cutaneous Leishmaniasis Preventive Behaviors
نشریه پرستاری ایران, 2007 Introduction & Aim: Cutaneous Leishmaniasis is the second common parasitic disease in Iran. According to several studies, insufficient knowledge of mothers about the prevention strategies related to occurrence of the disease in their children are ...
A. Hossein nejad Nayrisi +3 more
doaj
Pharmaceutics, 2022 Liposomal amphotericin B (AmB) or AmBisome® is the most effective and safe therapeutic agent for visceral leishmaniasis (VL), but its clinical efficacy is limited in cutaneous leishmaniasis (CL) and HIV/VL co-infection.
Guilherme S. Ramos +11 more
doaj +1 more source
Protein Science, Volume 35, Issue 7, July 2026.Abstract FAD/NAD(P)H‐dependent dehydrogenases form a structurally conserved family of redox enzymes that participate in essential metabolic processes across parasites and higher organisms. Among them, trypanothione reductase (TR) is a key component of the redox metabolism of Leishmania species and represents an attractive target for antileishmanial ...
Giulia Chiara Maria Perrone +15 more
wiley +1 more source
Natural killer cells in experimental and human leishmaniasis
Frontiers in Cellular and Infection Microbiology, 2012 Infections with parasites of the genus Leishmania lead to a rapid, but transient activation of natural killer (NK) cells. In mice activation of NK cells requires a toll-like-receptor 9-dependent stimulation of dendritic cells followed by the production ...
Christian eBogdan
doaj +1 more source
Pharmaceutics, 2023 Cutaneous leishmaniasis exhibits a wide spectrum of clinical manifestations; however, only a limited number of drugs are available and include Glucantime® and amphotericin B, which induce unacceptable side effects in patients, limiting their use.
Sarah Kymberly Santos de Lima +11 more
doaj +1 more source
Veterinary Medicine and Science, Volume 12, Issue 4, July 2026.This study investigated the epidemiology, risk factors and spatial distribution of cutaneous leishmaniasis in District Bajaur, Pakistan. Higher prevalence was observed among young males during summer, with lesions mainly on exposed body parts. Spatial analysis identified Khar, Loe Mamund and Salarzai as hotspots, highlighting the need for targeted ...
Murad Ali Khan +10 more
wiley +1 more source